Clinical-stage biopharmaceutical company developing oral small molecule therapies
1 AI-extracted insight from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Inventiva S.A..
The 1 sources with the most insights about Inventiva S.A. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Extremely bearish outlook ahead of binary clinical data readouts for its PPAR agonist program, characterized as heading toward zero.
Extremely bearish outlook ahead of binary clinical data readouts for its PPAR agonist program, characterized as heading toward zero.
Other assets that creators frequently mention in the same content as Inventiva S.A..
The most active sources covering Inventiva S.A. (IVA) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 1 AI-extracted insight about Inventiva S.A. (IVA) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Inventiva S.A. (IVA) most frequently also discuss GPRO, NBIS, ALMS, KNSL, MRNA. See the "Discussed alongside" section above for full asset pages.